The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Gene therapy for hemophilia
Open accessAbstract
Gene therapy offers the potential for a cure for patients with hemophilia by establishing continuous endogenous expression of factor VIII or factor IX (FIX) following transfer of a functional gene to replace the hemophilic patient’s own defective gene. The hemophilias are ideally suited for gene therapy because a small increment in blood factor levels (≥5% of normal) is associated with significant amelioration of bleeding phenotype in severely affected patients. In 2011, the St. Jude/UCL phase 1/2 trial was the first to provide clear evidence of a stable dose-dependent increase in FIX levels in patients with severe hemophilia B following a single administration of adeno-associated viral (AAV) vectors. Transgenic FIX expression has remained stable at ∼5% of normal in the high-dose cohort over a 7-year follow-up period, resulting in a substantial reduction in spontaneous bleeding and FIX protein usage without toxicity. This study has been followed by unparalleled advances in gene therapy for hemophilia A and B, leading to clotting factor activity approaching normal or near-normal levels associated with a “zero bleed rates” in previously severely affected patients following a single administration of AAV vectors. Thus, AAV gene therapies are likely to alter the treatment paradigm for hemophilia A and B. This review explores recent progress and the remaining limitations that need to be overcome for wider availability of this novel treatment of inherited bleeding disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Conversely, CpG enrichment negatively affected the outcome of gene therapy for hemophilia (47, 48).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [47]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“To circumvent recognition of the AAV genome by TLR9, development of CpG-depleted expression cassettes has become a major focus for clinical applications, while incorporation of TLR9 inhibitory sequences has been proposed as an alternative strategy.28,29,30”
From TLR9-independent CD8+ T cell responses in hepatic AAV gene transfer through IL-1R1-MyD88 signaling (2024) · cites this paper as [28]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“While we have not tested CpG depletion in scAAV vectors in this study, clinical trial results support that such a vector is also less prone to CD8+ T cell activation, at least against capsid (47, 52).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [47]
Experimental — accuracy not yet measuredIn the citing paper
“Clinical experience with hepatic AAV gene transfer for hemophilia suggests that CpG motifs contribute to the loss of therapeutic expression and that immune suppression, when still needed, is more effective when using CpG depleted vectors (45–47).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [47]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia
Manco-Johnson, M. J., Abshire, T. C., Shapiro, A. D., Riske, B., Hacker, M. R., Kilcoyne, R., Ingram, J. D., Manco-Johnson, M. L., Funk, S., Jacobson, L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067659 · Cited by 1,950 · cited 1×
“If started in early childhood, arthropathy can be largely prevented by regular prophylaxis.(3) When continued throughout life, prophylaxis leads to near normalization of life expectancy.”
BackgroundNovel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520 · cited 2×
“70% for AAV2) enabled exclusion of fewer subjects with preexisting humoral immunity to AAV8.(23)”
BackgroundEmicizumab Prophylaxis in Hemophilia A with Inhibitors
Oldenburg, J., Mahlangu, J. N., Kim, B., Schmitt, C., Callaghan, M. U., Young, G., Santagostino, E., Kruse-Jarres, R., Negrier, C., Kessler, C., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1703068 · Cited by 1,121 · cited 1×
“Unlike FVIII, emicizumab is active in plasma all of the time and is associated with microangiopathy and thrombosis, particularly when used in combination with activated prothrombin complex concentrates.(8) Other novel approaches entail the lowering of endogenous anticoagulants, such as antithrombin or tissue factor pa…”
BackgroundHemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant
George, L. A., Sullivan, S. K., Giermasz, A., Rasko, J. E. J., Samelson-Jones, B. J., Ducore, J., Cuker, A., Sullivan, L. M., Majumdar, S., Teitel, J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708538 · Cited by 762 · cited 2×
“This led to the hypothesis that an excess of unmethylated CpG motifs, which are common in bacterial, but not mammalian, DNA, triggered a Toll-like receptor 9 response, leading to loss of transduced hepatocytes with an associated transaminitis that is not responsive to corticosteroids.28 In the gene therapy trial that…”
BackgroundInfluentialAAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
Manno, C. S., Chew, A. J., Hutchison, S., Larson, P. J., Herzog, R. W., Arruda, V. R., Tai, S. J., Ragni, M. V., Thompson, A., Ozelo, M., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3296 · Cited by 749
AAV5–Factor VIII Gene Transfer in Severe Hemophilia A
Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G. F., Wong, W. Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708483 · Cited by 694 · cited 2×
“Highly encouraged by these results, a new cohort of 6 patients was treated at a lower dose level of 4e13 vg/kg, leading to sustained FVIII activity of ~30% at 1 year after gene therapy.(33) Across the 13 patients in the 4e13- and 6e13-dose levels, a .”
MethodAAV vector integration sites in mouse hepatocellular carcinoma
Donsante, A., Miller, D. G., Li, Y., Vogler, C., Brunt, E. M., Russell, D. W., & Sands, M. S. (2007) · Science · doi:10.1126/science.1142658 · Cited by 662 · cited 1×
“An increased incidence of hepatocellular carcinoma has been reported in the mucopolysaccharidoses type VII mouse model following perinatal gene transfer of AAV, potentially through integration and disruption of an imprinted region rich in microRNAs and small nucleolar RNAs on mouse chromosome 12.(41) Subsequent studie…”
BackgroundDarby, S. C., Kan, S. W., Spooner, R. J., Giangrande, P. L. F., Hill, F. G. H., Hay, C. R. M., Lee, C. A., Ludlam, C. A., & Williams, M. (2007) · Blood · doi:10.1182/blood-2006-10-050435 · Cited by 511 · cited 1×
“When continued throughout life, prophylaxis leads to near normalization of life expectancy.(4) The relatively short half-life of FVIII and FIX in the circulation necessitates frequent IV administration of factor concentrates ($2-3 times a week), which is demanding and extremely expensive.”
BackgroundRecurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas
Nault, J.-C., Datta, S., Imbeaud, S., Franconi, A., Mallet, M., Couchy, G., Letouzé, E., Pilati, C., Verret, B., Blanc, J.-F., et al. (2015) · Nature Genetics · doi:10.1038/ng.3389 · Cited by 489
Factor VIII–Mimetic Function of Humanized Bispecific Antibody in Hemophilia A
Shima, M., Hanabusa, H., Taki, M., Matsushita, T., Sato, T., Fukutake, K., Fukazawa, N., Yoneyama, K., Yoshida, H., & Nogami, K. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1511769 · Cited by 478 · cited 1×
“For instance, a bispecific antibody (emicizumab) with 1 arm binding to FIXa and the other to FX facilitates the conversion of FX into its active form, leading to restoration of hemostasis to a degree comparable to an FVIII level of ~15% of normal in hemophilia A patients with or without inhibitors.(7) Emicizumab has a…”
Background
Research works printed but not linked: 3
- Roth, 2002, Implantation of non-viral ex vivo genetically modified autologous dermal fibroblasts that express B-domain deleted human factor VIII in 12 severe hemophilia A study subjects, Blood, 100, 116a
- George, 2018, SPK-8011: Preliminary results from a phase 1/2 trial of investigational gene therapy for hemophilia A, Haemophilia, 24, 30
- Konkle, 2019, Initial results of the Alta study, a phase 1/2, open label, adaptive, dose-ranging study to assess the safety and tolerability of SB-525 gene therapy in adult subjects with severe hemophilia A
Cited by
Immune Responses to Viral Gene Therapy Vectors
Shirley, J. L., de Jong, Y. P., Terhorst, C., & Herzog, R. W. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.01.001 · Cited by 788
“Data from clinical trials suggest that CpG enrichment negatively affected the outcome of liver-directed gene therapy for hemophilia.(56,58) Recently presented data suggest that long-term FIX expression despite CpG-enriched vector sequences may be associated at least in some patients with polymorphism in the IL6R gene.”
BackgroundGene Therapy with Etranacogene Dezaparvovec for Hemophilia B
Pipe, S. W., Leebeek, F. W. G., Recht, M., Key, N. S., Castaman, G., Miesbach, W., Lattimore, S., Peerlinck, K., Van der Valk, P., Coppens, M., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2211644 · Cited by 364
Berntorp, E., Fischer, K., Hart, D. P., Mancuso, M. E., Stephensen, D., Shapiro, A. D., & Blanchette, V. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00278-x · Cited by 328
Delivery of CRISPR-Cas tools for in vivo genome editing therapy: Trends and challenges
Taha, E. A., Lee, J., & Hotta, A. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.013 · Cited by 259
Viral Vectors in Gene Therapy: Where Do We Stand in 2023?
Lundstrom, K. (2023) · Viruses · doi:10.3390/v15030698 · Cited by 187
“In another approach, self ‐ complementary AAV2 vectors expressing FIX (scAAV2 ‐ FIX) showed stable FIX produc ‐ tion for 7 years, contributing to substantial reduction in bleeding in hemophilia B patients [176].”
Influential
Metadata
- Authors
- Nathwani, A. C.
- Affiliations
- Royal Free London NHS Foundation Trust (GB)
- Corresponding author
- Nathwani, Amit C.
- ORCID
- Nathwani, Amit C.
- Venue
- Hematology
- Publisher
- American Society of Hematology
- Published
- 2019-12-06
- Volume
- 2019
- Issue
- 1
- Pages
- 1-8
- ISSN
- 1520-4383 (ISSN-L)
- 1520-4391
- PMC
- PMC6913446
- OpenAlex
- W2994542907
- Cited by
- 140
- References
- 47
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 21 · 2023: 22 · 2022: 31 · 2021: 29 · 2020: 17 · 2019: 1
- FWCI
- 3.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Hematology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute for Health and Care Research (NF-SI-0513-10071)
- Rosetrees Trust
- Medical Research Council (MR/L013185/1)
- Topics
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Keywords
- gene therapy, hemophilia, hemophilia A, hemophilia B, adeno-associated virus vectors, factor VIII, factor IX, bleeding phenotype, inherited bleeding disorders
- MeSH terms
- Animals, Clinical Trials as Topic, Genetic Vectors, Hemophilia A, Humans, Genetic Therapy, Gene Transfer Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gene therapy for hemophilia. https://app.cochat.ai/papers/10.1182/hematology.2019000007
- The paper
- Nathwani, A. C. (2019). Gene therapy for hemophilia. Hematology. https://doi.org/10.1182/hematology.2019000007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.